IDH1 and IDH2 Mutations in Gliomas

Cited by (1,012)

Items 401–500 of 1,012

1. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline
   Nimish A. Mohile, Hans J. Messersmith, Na Tosha Gatson, Andreas Felix Hottinger, Andrew Lassman, Jordan Morton, Douglas Ney, Phioanh Leia Nghiemphu, Adriana Olar, Jeffery Olson et al. · 2021 · Journal of Clinical Oncology
2. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML
   Chaturvedi, Anuhar, Araujo Cruz, Michelle Maria, Jyotsana, Nidhi, Sharma, Amit, Yun, Haiyang, Görlich, Kerstin, Wichmann, Martin, Schwarzer, Adrian, Preller, Matthias, Thol, Felicitas et al. · 2013 · Blood
3. Lactate dehydrogenase A silencing in IDH mutant gliomas
   Chesnelong, Charles, Chaumeil, Myriam M., Blough, Michael D., Al-Najjar, Mohammad, Stechishin, Owen D., Chan, Jennifer A., Pieper, Russell O., Ronen, Sabrina M., Weiss, Samuel, Luchman, H. Artee et al. · 2014 · Neuro-Oncology
4. Purine synthesis promotes maintenance of brain tumor initiating cells in glioma
   Xiuxing Wang, Kailin Yang, Qi Xie, Qiulian Wu, Stephen C. Mack, Yu Shi, Leo J.Y. Kim, Briana C. Prager, William A. Flavahan, Xiaojing Liu et al. · 2017 · Nature Neuroscience
5. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone
   Remco Jurriaan Molenaar, Dagmar Verbaan, Simona Lamba, Carlo Zanon, Judith W. M. Jeuken, Sandra Boots‐Sprenger, Pieter Wesseling, Theo J.M. Hulsebos, Dirk Troost, Angela A. van Tilborg et al. · 2014 · Neuro-Oncology
6. Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer
   Owen Clark, Katharine E. Yen, Ingo K. Mellinghoff · 2016 · Clinical Cancer Research
7. Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma
   Zenon D. Konteatis, Erin Artin, Brandon Nicolay, Kimberly S. Straley, Anil K. Padyana, Lei Jin, Yue Chen, Rohini Narayaraswamy, Shuilong Tong, Feng Wang et al. · 2020 · ACS Medicinal Chemistry Letters
8. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents
   Wang, Pu, Wu, Jing, Ma, Shenghong, Zhang, Lei, Yao, Jun, Hoadley, Katherine A., Wilkerson, Matthew D., Perou, Charles M., Guan, Kun-Liang, Ye, Dan et al. · 2015 · Cell Reports
9. 5-hydroxymethylcytosine and its potential roles in development and cancer
   Gerd P. Pfeifer, Swati Kadam, Seung‐Gi Jin · 2013 · Epigenetics & Chromatin
10. Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo
    Janeta V. Popovici-Müller, Jeffrey O. Saunders, Francesco G. Salituro, Jeremy M. Travins, Shunqi Yan, Fang Zhao, Stefan Größ, Lenny Dang, Katharine E. Yen, Hua Yang et al. · 2012 · ACS Medicinal Chemistry Letters
11. Isocitrate Dehydrogenase Mutation and ( <i>R</i> )-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development
    Dang, Lenny, Su, Shin-San Michael · 2017 · Annual Review of Biochemistry
12. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation
    Wen‐Chien Chou, Hsin‐An Hou, Chien‐Yuan Chen, Jih‐Luh Tang, Ming Yao, Woei Tsay, Bor-Shen Ko, Shang‐Ju Wu, Shang‐Yi Huang, Szu-Chun Hsu et al. · 2010 · Blood
13. Seizures and gliomas — towards a single therapeutic approach
    Gilles Huberfeld, Charles J. Vecht · 2016 · Nature Reviews Neurology
14. How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges, opportunities and models
    Marike W. van Gisbergen, An M. Voets, Maud H. W. Starmans, I.F.M. de Coo, Rana Yadak, Roland F. Hoffmann, Paul Christopher Boutros, Hubert J.M. Smeets, Ludwig Jerome Dubois, Philippe Lambin · 2015 · Mutation Research/Reviews in Mutation Research
15. Cancer genome sequencing: a review
    Elaine R. Mardis, R. K. Wilson · 2009 · Human Molecular Genetics
16. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice
    Michael Weller, Roger Stupp, Monika E. Hegi, Martin J. van den Bent, J. C. Tonn, Marc Sanson, Wolfgang Wick, Guido Reifenberger · 2012 · Neuro-Oncology
17. Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d -2-Hydroxyglutarate
    Jing Fan, Xin Teng, Ling Liu, Katherine R. Mattaini, Ryan Looper, Matthew G. Vander Heiden, Joshua D. Rabinowitz · 2014 · ACS Chemical Biology
18. Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis
    Myra Ellen Van Linde, Cyrillo G. Brahm, Philip C. De Witt Hamer, Jaap C. Reijneveld, Anna M E Bruynzeel, William Peter Vandertop, Peter M. van de Ven, Michiel Wagemakers, Hiska L. van der Weide, Roelien H. Enting et al. · 2017 · Journal of Neuro-Oncology
19. Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With <i>IDH</i> -Mutant Glioma
    Choi, Changho, Raisanen, Jack M., Ganji, Sandeep K., Zhang, Song, McNeil, Sarah S., An, Zhongxu, Madan, Akshay, Hatanpaa, Kimmo J., Vemireddy, Vamsidhara, Sheppard, Christie A. et al. · 2016 · Journal of Clinical Oncology
20. TET proteins and 5‐methylcytosine oxidation in hematological cancers
    Myunggon Ko, Jungeun An, William A. Pastor, Sergei B. Koralov, Klaus Rajewsky, Anjana Rao · 2014 · Immunological Reviews
21. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status
    Susanne Schnittger, Claudia Haferlach, Madlen Ulke, Tamara Alpermann, Wolfgang Kern, Torsten Haferlach · 2010 · Blood
22. Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair
    Yanxin Lu, Jakub Kwintkiewicz, Yang Liu, Katherine Tech, Lauren N. Frady, Yu-Ting Su, Wendy Bautista, Seog In Moon, Jeffrey M. Macdonald, Matthew G. Ewend et al. · 2017 · Cancer Research
23. Characterizing DNA methylation alterations from The Cancer Genome Atlas
    Weisenberger, Daniel J. · 2014 · Journal of Clinical Investigation
24. Tumor-Infiltrating Lymphocytes in Glioblastoma Are Associated with Specific Genomic Alterations and Related to Transcriptional Class
    Caleb Rutledge, Jun Kong, Jingjing Gao, David A. Gutman, Lee Cooper, Christina Appin, Yuna Park, Lisa M. Scarpace, Tom Mikkelsen, Mark L. Cohen et al. · 2013 · Clinical Cancer Research
25. An in vivo patient-derived model of endogenous IDH1-mutant glioma
    Hema Artee Luchman, Owen D.M. Stechishin, Nam Hoang Dang, Michael D. Blough, Charles Chesnelong, John J. Kelly, Shaun A. Nguyen, Jennifer Ai-wen Chan, Aalim M. Weljie, J. Greg Cairncross et al. · 2011 · Neuro-Oncology
26. Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease
    Rona D. Yaeger, Manish A. Shah, Vincent A. Miller, Judith R. Kelsen, Kai Wang, Zachary J. Heins, Jeffrey S. Ross, Yuting He, Eric M. Sanford, Rhonda K. Yantiss et al. · 2016 · Gastroenterology
27. The role of imaging in the management of progressive glioblastoma
    Timothy Charles Ryken, Nafi Aygün, Johnathan Morris, Marin Leigh Schweizer, Rajeshwari Nair, Cassandra Nichole Spracklen, Steven N. Kalkanis, Jeffrey J. Olson · 2014 · Journal of Neuro-Oncology
28. <i>IDH2</i> Mutations in Patients with <scp>d</scp> -2-Hydroxyglutaric Aciduria
    Kranendijk, Martijn, Struys, Eduard A., van Schaftingen, Emile, Gibson, K. Michael, Kanhai, Warsha A., van der Knaap, Marjo S., Amiel, Jeanne, Buist, Neil R., Das, Anibh M., de Klerk, Johannis B. et al. · 2010 · Science
29. Females have the survival advantage in glioblastoma
    Quinn T. Ostrom, Joshua B. Rubin, Justin Durla Lathia, Michael E. Berens, Jill S. Barnholtz‐Sloan · 2018 · Neuro-Oncology
30. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma
    Benedikt Wiestler, David Capper, Martin Sill, David Jones, Volker Hovestadt, Dominik Sturm, Christian Koelsche, Anna Bertoni, Leonille Schweizer, Andrey Korshunov et al. · 2014 · Acta Neuropathologica
31. Molecular and cellular heterogeneity: the hallmark of glioblastoma
    Diane J. Aum, David H. Kim, Thomas Beaumont, Eric C. Leuthardt, Gavin P. Dunn, Albert H. Kim · 2014 · Neurosurgical FOCUS
32. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma
    Macarena I. de la Fuente, Robert J. Young, Jennifer Rubel, Marc K. Rosenblum, Jamie Tisnado, Samuel R. Briggs, Julio Arevalo Perez, Justin R. Cross, Carl Campos, Kimberly S. Straley et al. · 2015 · Neuro-Oncology
33. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis
    Felicitas R. Thol, E. M. Weissinger, J. Krauter, Katharina Wagner, Frédérik Damm, M. Wichmann, Gudrun Göhring, Christiane Schumann, G. Bug, Oliver Gerhard Ottmann et al. · 2010 · Haematologica
34. IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival
    Severina Leu, Stefanie von Felten, Stephan Frank, Erik Vassella, István Vajtai, Elisabeth Taylor, M. Schulz, Gregor Hütter, Juergen Hench, Philippe Schucht et al. · 2013 · Neuro-Oncology
35. Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment
    Belén Delgado-Martín, Miguel Ángel Medina · 2020 · Advanced Science
36. Identification of additional IDH mutations associated with oncometabolite R(−)-2-hydroxyglutarate production
    Patrick S. Ward, Justin R. Cross, Chao Lü, Oliver Weigert, Omar Ibrahim Abdel-Wahab, Ross L. Levine, David M. Weinstock, Kim A. Sharp, Craig B. Thompson · 2011 · Oncogene
37. DNA repair mechanisms and their clinical impact in glioblastoma
    Hélène Erasimus, Matthieu Gobin, Simone P. Niclou, Eric Van Dyck · 2016 · Mutation Research/Reviews in Mutation Research
38. Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in <i>IDH</i> -Mutant Gliomas
    Wakimoto, Hiroaki, Tanaka, Shota, Curry, William T., Loebel, Franziska, Zhao, Dan, Tateishi, Kensuke, Chen, Juxiang, Klofas, Lindsay K., Lelic, Nina, Kim, James C. et al. · 2014 · Clinical Cancer Research
39. Targeting Metabolic Remodeling in Glioblastoma Multiforme
    Amparo Wolf, Sameer Agnihotri, Abhijit Guha · 2010 · Oncotarget
40. The emerging role of fumarate as an oncometabolite
    Yang, Ming, Soga, Tomoyoshi, Pollard, Patrick J., Adam, Julie · 2012 · Frontiers in Oncology
41. Addressing Diffuse Glioma as a Systemic Brain Disease With Single-Cell Analysis
    David Capper · 2011 · Archives of Neurology
42. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide
    Hendrikus Jan Dubbink, Walter Taal, Ronald van Marion, Johan M. Kros, Irene van Heuvel, Jacoline E. C. Bromberg, Bernard A. Zonnenberg, Christian B. L. Zonnenberg, Tjeerd J. Postma, Johanna M. M. Gijtenbeek et al. · 2009 · Neurology
43. Driver mutations of cancer epigenomes
    David M. Roy, Logan A. Walsh, Timothy An-thy Chan · 2014 · Protein & Cell
44. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia
    Felicitas R. Thol, Frédérik Damm, Katharina Wagner, Gudrun Göhring, Brigitte Schlegelberger, Dieter F. Hoelzer, Michael Lübbert, Wolfgang F.W. Heit, Lothar Kanz, Günter Schlimok et al. · 2010 · Blood
45. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas
    Liwei Zhang, Lee H. Chen, Hong Wan, Rui Ryan Yang, Zhaohui Wang, Jie Feng, Shaohua Yang, Siân Jones, Sizhen Wang, Weixin Zhou et al. · 2014 · Nature Genetics
46. Famine versus feast: understanding the metabolism of tumors in vivo
    Jared R. Mayers, Matthew G. Vander Heiden · 2015 · Trends in Biochemical Sciences
47. CDKN2ALoss Is Associated With Shortened Overall Survival in Lower-Grade (World Health Organization Grades II–III) Astrocytomas
    Gerald F. Reis, Melike Pekmezci, Helen M. Hansen, Terri Rice, Roxanne E. Marshall, Annette M. Molinaro, Joanna J. Phillips, Hannes S. Vogel, John K. Wiencke, Margaret Wrensch et al. · 2015 · Journal of Neuropathology & Experimental Neurology
48. Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations
    Christian Johannes Hartmann, Bettina Hentschel, Matthias Simon, Manfred Westphal, Gabriele Schackert, Jörg Christian Tonn, Markus Loeffler, Guido Reifenberger, Torsten Pietsch, Andreas von Deimling et al. · 2013 · Clinical Cancer Research
49. Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells
    Fabian V. Filipp, David A. Scott, Ze’ev A. Ronai, Andrei L. Osterman, Jeffrey W. Smith · 2012 · Pigment Cell & Melanoma Research
50. Glioma Biology and Molecular Markers
    Adam Louis Cohen, Howard Colman · 2014 · Cancer treatment and research
51. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms
    Animesh Dev Pardanani, Terra L. Lasho, Christy M. Finke, Ming Mai, Rebecca F. McClure, Ayalew Tefferi · 2010 · Leukemia
52. IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children’s Oncology Group
    for the Children’s Oncology Group, Ian F. Pollack, Ronald L. Hamilton, Robert William Sobol, Marina N. Nikiforova, Maureen A. Lyons‐Weiler, William A. LaFramboise, Peter C. Burger, Daniel Jay Brat, Marc K. Rosenblum et al. · 2010 · Child s Nervous System
53. Hallmarks of glioblastoma: a systematic review
    Dorte Schou Nørøxe, Hans Skovgaard Poulsen, Ulrik Lassen · 2016 · ESMO Open
54. The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation
    Remco Jurriaan Molenaar, Tomas Radivoyevitch, Jaroslaw Pawel Maciejewski, Cornelis J.F. Van Noorden, Fonnet E. Bleeker · 2014 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
55. Cell metabolism: An essential link between cell growth and apoptosis
    Emily Ferguson Mason, Jeffrey C. Rathmell · 2010 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
56. Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium
    Kenneth Aldape, Samirkumar B. Amin, David M. Ashley, Jill S. Barnholtz‐Sloan, Amanda J Bates, Rameen Beroukhim, Christoph Bock, Daniel Jay Brat, Elizabeth B. Claus, J Costello et al. · 2018 · Neuro-Oncology
57. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition
    Chong Chen, Yu Liu, Chao Lü, Justin R. Cross, John P. Morris, Aditya Shroff, Patrick S. Ward, James E. Bradner, Craig B. Thompson, Scott W. Lowe · 2013 · Genes & Development
58. Glioma Stem Cell–Specific Superenhancer Promotes Polyunsaturated Fatty-Acid Synthesis to Support EGFR Signaling
    Ryan C. Gimple, Reilly L. Kidwell, Leo J.Y. Kim, Tengqian Sun, Anthony D. Gromovsky, Qiulian Wu, Megan E Wolf, Deguan Lv, Shruti Bhargava, Li Jiang et al. · 2019 · Cancer Discovery
59. The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular Compartmentalization
    Patrick S. Ward, Chao Lü, Justin R. Cross, Omar Ibrahim Abdel-Wahab, Ross L. Levine, Gary K. Schwartz, Craig B. Thompson · 2012 · Journal of Biological Chemistry
60. The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway
    Carbonneau, Mélissa, M. Gagné, Laurence, Lalonde, Marie-Eve, Germain, Marie-Anne, Motorina, Alena, Guiot, Marie-Christine, Secco, Blandine, Vincent, Emma E., Tumber, Anthony, Hulea, Laura et al. · 2016 · Nature Communications
61. Dysembryoplastic Neuroepithelial Tumors Share with Pleomorphic Xanthoastrocytomas and Gangliogliomas BRAFV600E Mutation and Expression
    Céline Chappé, Laëtitia Padovani, Didier Scavarda, Fabien Forest, Isabelle Nanni‐Metellus, Anderson Loundou, Sandy Mercurio, Fréderic Fina, Gabriel Lena, Carole Colin et al. · 2013 · Brain Pathology
62. Magnetic Resonance of 2-Hydroxyglutarate in IDH1 -Mutated Low-Grade Gliomas
    Adam Elkhaled, Llewellyn E. Jalbert, Joanna J. Phillips, Hikari A. I. Yoshihara, Rupa Parvataneni, Radhika Srinivasan, G. Bourne, Mitchel Stuart Berger, Susan Marina Chang, Soonmee Cha et al. · 2012 · Science Translational Medicine
63. Hypoxia: The Cornerstone of Glioblastoma
    Marta Doménech, Ainhoa Hernández, Andrea Plaja, Eva Martinez‐Balibrea, Carmen Balañá · 2021 · International Journal of Molecular Sciences
64. Applications of metabolomics to study cancer metabolism
    Kaushik, Akash K., DeBerardinis, Ralph J. · 2018 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
65. Current concepts in clinical radiation oncology
    Michael Orth, Kirsten Lauber, Maximilian Niyazi, Anna A. Friedl, Minglun Li, Cornelius Maihöfer, Lars Schüttrumpf, Anne Ernst, Olivier M. Niemoeller, Claus Belka · 2013 · Radiation and Environmental Biophysics
66. A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors
    Ingmar Blümcke, Eleonora Aronica, Horst Urbach, Andreas V. Alexopoulos, Jorge Alvaro Gonzalez-Martinez · 2014 · Acta Neuropathologica
67. Oncometabolites: Unconventional triggers of oncogenic signalling cascades
    Marco Sciacovelli, Christian Frezza · 2016 · Free Radical Biology and Medicine
68. Imaging Correlates of Adult Glioma Genotypes
    Marion Smits, Martin J. van den Bent · 2017 · Radiology
69. Acute Myeloid Leukemia With IDH1 or IDH2 Mutation
    Keyur Pravinchandra Patel, Farhad Ravandi, Deqin Ma, Abhaya V. Paladugu, Bedia A. Barkoh, Leonard Jeffrey Medeiros, Rajyalakshmi Luthra · 2010 · American Journal of Clinical Pathology
70. Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo
    Stefan Pusch, Sonja Krausert, Viktoria Fischer, Jörg Balß, Martina Ott, Daniel Schrimpf, David Capper, Felix Sahm, Jessica Eisel, Ann-Christin Beck et al. · 2017 · Acta Neuropathologica
71. A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence
    Camila Ferreira de Souza, Thaís S. Sabedot, Tathiane Maistro Malta, Lindsay C. Stetson, Olena Morozova, Artem Sokolov, Peter W. Laird, Maciej Wiznerowicz, Antonio Iavarone, James Snyder et al. · 2018 · Cell Reports
72. Decreased 5-Hydroxymethylcytosine Is Associated with Neural Progenitor Phenotype in Normal Brain and Shorter Survival in Malignant Glioma
    Brent A. Orr, Michael C. Haffner, William G. Nelson, Srinivasan Yegnasubramanian, Charles G. Eberhart · 2012 · PLoS ONE
73. Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment
    Federica Sotgia, Ubaldo Martinez‐Outschoorn, Stephanos Pavlides, Anthony Howell, Richard G. Pestell, Michael P. Lisanti · 2011 · Breast Cancer Research
74. 2016 Updates to the WHO Brain Tumor Classification System: What the Radiologist Needs to Know
    Derek Richard Johnson, Julie B. Guerin, Caterina Giannini, Jonathan M. Morris, Lawrence J. Eckel, Timothy J. Kaufmann · 2017 · Radiographics
75. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
    Bill H. Diplas, Xujun He, Jacqueline A. Brosnan‐Cashman, Heng Liu, Lee H. Chen, Zhaohui Wang, Casey J. Moure, Patrick J. Killela, Daniel B. Loriaux, Eric Lipp et al. · 2018 · Nature Communications
76. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation
    Christopher G. Duncan, Benjamin G. Barwick, Genglin Jin, Carlo Rago, Priya Kapoor-Vazirani, Doris R. Powell, Jen‐Tsan Chi, Darell D. Bigner, Paula M. Vertino, Hai Yan · 2012 · Genome Research
77. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate
    Ovidiu C. Andronesi, Otto Rapalino, Elizabeth Robins Gerstner, Andrew S. Chi, Tracy T. Batchelor, Daniel P. Cahill, Alma Gregory Sorensen, Bruce Robert Rosen · 2013 · Journal of Clinical Investigation
78. The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations
    Andreas von Deimling, Andrey Korshunov, Christian Johannes Hartmann · 2010 · Brain Pathology
79. Genetic architecture of colorectal cancer
    Ulrike Peters, Stephanie A. Bien, Niha Zubair · 2015 · Gut
80. Mutant IDH1 and thrombosis in gliomas
    Dusten J. Unruh, Steven R. Schwarze, Laith Khoury, Cheddhi Thomas, Meijing Wu, Li Chen, Rui Chen, Yinxing Liu, Margaret A. Schwartz, Christina Amidei et al. · 2016 · Acta Neuropathologica
81. Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance
    Evan Noch, Rohan R. Ramakrishna, Rajiv Magge · 2018 · World Neurosurgery
82. Metabolism unhinged: IDH mutations in cancer
    John R. Prensner, Arul M. Chinnaiyan · 2011 · Nature Medicine
83. Recent developments in myelodysplastic syndromes
    Rafael L. Bejar, David P. Steensma · 2014 · Blood
84. Precision histology: how deep learning is poised to revitalize histomorphology for personalized cancer care
    Ugljesa Djuric, Gelareh Mohammed Zadeh, Kenneth Aldape, Phedias Diamandis · 2017 · npj Precision Oncology
85. Glioblastoma multiforme: a review of therapeutic targets
    Okezie Obasi Kanu, Ankit Indravadan Mehta, Chunhui Di, Ningjing Lin, Kathy Bortoff, Darell D. Bigner, Hai Yan, David Cory Adamson · 2009 · Expert Opinion on Therapeutic Targets
86. Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?
    Christian Johannes Hartmann, Bettina Hentschel, Marcos Soares Tatagiba, Johannes Schramm, Oliver Schnell, Clemens Seidel, Robert J. Stein, Guido Reifenberger, Torsten Pietsch, Andreas von Deimling et al. · 2011 · Clinical Cancer Research
87. Predicting IDH mutation status in grade II gliomas using amide proton transfer‐weighted (APTw) MRI
    Shanshan Jiang, Tianyu Zou, Charles G. Eberhart, Maria A.V. Villalobos, Hye‐Young Heo, Yi Zhang, Yu Wang, Xianlong Wang, Hao Yu, Yongxing Du et al. · 2017 · Magnetic Resonance in Medicine
88. Altered cancer metabolism in mechanisms of immunotherapy resistance
    Rishab Ramapriyan, Mauricio S. Caetano, Hampartsoum B. Barsoumian, Ana Carolina Paschoalini Mafra, Érika Pereira Zambalde, Hari Menon, Efrosini Tsouko, James William Welsh, María Angélica Cortez · 2018 · Pharmacology & Therapeutics
89. Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications
    Benjamin T. Himes, Philipp A. Geiger, Katayoun Ayasoufi, Adip Guruprasad Bhargav, Desmond A. Brown, Ian F. Parney · 2021 · Frontiers in Oncology
90. Cancer Metabolism and Drug Resistance
    Mahbuba Rahman, Mohammad R. Hasan · 2015 · Metabolites
91. Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma
    Erika C. Cosset, Sten Ilmjärv, Valérie Dutoit, Kathryn C. Elliott, Tami Von Schalscha, Maria F. Camargo, Alexander Reiss, Toshiro Moroishi, Laetitia Seguin, German G. Gomez et al. · 2017 · Cancer Cell
92. Oncogene-Directed Alterations in Cancer Cell Metabolism
    Nagarajan, Arvindhan, Malvi, Parmanand, Wajapeyee, Narendra · 2016 · Trends in Cancer
93. Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms
    Songtao Qi, Lei Yu, HEZHEN LI, Yang-hui Ou, Xiaoyu Qiu, Yanqing Ding, Hui-xia Han, XUELIN ZHANG · 2014 · Oncology Letters
94. The Metabolomic Signature of Malignant Glioma Reflects Accelerated Anabolic Metabolism
    Prakash Chinnaiyan, Elizabeth Kensicki, Gregory C. Bloom, Antony Herold Prabhu, Bhaswati Sarcar, Soumen Kahali, Steven A. Eschrich, Xiaotao Qu, Peter A. Forsyth, Robert J. Gillies · 2012 · Cancer Research
95. Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease
    Serena Tommasini-Ghelfi, Kevin Murnan, Fotini M. Kouri, Akanksha Mahajan, Jasmine May, Alexander H. Stegh · 2019 · Science Advances
96. Emerging Therapies for Glioblastoma
    Alissa A. Thomas, Cameron Brennan, Lisa Marie DeAngelis, Antonio M. P. Omuro · 2014 · JAMA Neurology
97. Role of Surgical Resection in Low- and High-Grade Gliomas
    Shawn L. Hervey‐Jumper, Mitchel Stuart Berger · 2014 · Current Treatment Options in Neurology
98. Genetic profile of astrocytic and oligodendroglial gliomas
    Hiroko Ohgaki, Paul Kleihues · 2011 · Brain Tumor Pathology
99. Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
    Niklas Thon, Simone Kreth, Friedrich Wilhelm Kreth · 2013 · OncoTargets and Therapy
100. Radioresistance in Glioblastoma and the Development of Radiosensitizers
     Md. Yousuf Ali, Claudia R. Oliva, Abu Shadat Mohammod Noman, Bryan G. Allen, Prabhat C. Goswami, Yousef Zakharia, Varun Monga, Douglas R. Spitz, John Michael Buatti, Corinne E. Griguer · 2020 · Cancers